413 results on '"Vencovsky, Jiri"'
Search Results
2. Discovery of new myositis genetic associations through leveraging other immune-mediated diseases
- Author
-
Reales, Guillermo, Amos, Christopher I., Benveniste, Olivier, Chinoy, Hector, De Bleecker, Jan, De Paepe, Boel, Doria, Andrea, Gregersen, Peter K., Lamb, Janine A., Limaye, Vidya, Lundberg, Ingrid E., Machado, Pedro M., Maurer, Britta, Miller, Frederick W., Molberg, Øyvind, Pachman, Lauren M., Padyukov, Leonid, Radstake, Timothy R., Reed, Ann M., Rider, Lisa G., Rothwell, Simon, Selva-O'Callaghan, Albert, Vencovský, Jiri, Wedderburn, Lucy R., and Wallace, Chris
- Published
- 2024
- Full Text
- View/download PDF
3. Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network
- Author
-
Espinosa-Ortega, Fabricio, Lodin, Karin, Dastmalchi, Maryam, Vencovsky, Jiri, Diederichsen, Louise P, Shinjo, Samuel Katsuyuki, Danieli, Maria Giovanna, Selva-O'Callaghan, Albert, de Visser, Marianne, Griger, Zoltan, Ceribelli, Angela, Gómez-Martin, Diana, Andersson, Helena, Vázquez-Del Mercado, Mónica, Chinoy, Hector, Lilleker, James B, New, Paul, Krogh, Niels S, Lundberg, Ingrid E, and Alexanderson, Helene
- Published
- 2024
- Full Text
- View/download PDF
4. Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies
- Author
-
Leclair, Valérie, Notarnicola, Antonella, Kryštůfková, Olga, Mann, Herman, Andersson, Helena, Diederichsen, Louise Pyndt, Vencovský, Jiri, Holmqvist, Marie, Lundberg, Ingrid E., Steele, Russell J., and Hudson, Marie
- Published
- 2024
- Full Text
- View/download PDF
5. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
- Author
-
Christiansen, Sara Nysom, Horskjær Rasmussen, Simon, Pons, Marion, Michelsen, Brigitte, Glintborg, Bente, Gudbjornsson, Bjorn, Grondal, Gerdur, Vencovsky, Jiri, Loft, Anne Gitte, Rotar, Ziga, Pirkmajer, Katja Perdan, Nissen, Michael J., Baranová, Jana, Macfarlane, Gary J., Jones, Gareth T., Iannone, Florenzo, Caporali, Roberto, Laas, Karin, Vorobjov, Sigrid, Giuseppe, Daniela Di, Olofsson, Tor, Provan, Sella Aarrestad, Fagerli, Karen Minde, Castrejon, Isabel, Otero-Varela, Lucia, van de Sande, Marleen, van der Horst-Bruinsma, Irene, Nordström, Dan, Kuusalo, Laura, Bernardes, Miguel, Hetland, Merete Lund, Østergaard, Mikkel, and Midtbøll Ørnbjerg, Lykke
- Published
- 2024
- Full Text
- View/download PDF
6. Patient global assessment and inflammatory markers in patients with idiopathic inflammatory myopathies – A longitudinal study
- Author
-
Lodin, Karin, Espinosa-Ortega, Fabricio, Dastmalchi, Maryam, Vencovsky, Jiri, Andersson, Helena, Chinoy, Hector, Lilleker, James B., Shinjo, Samuel Katsuyuki, Maurer, Britta, Griger, Zoltan, Ceribelli, Angela, Torres-Ruiz, Jiram, Mercado M., Vazquez-Del, Leonard, Dag, Alexanderson, Helene, and Lundberg, Ingrid E.
- Published
- 2024
- Full Text
- View/download PDF
7. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Author
-
Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund
- Published
- 2023
- Full Text
- View/download PDF
8. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
- Author
-
Bianchi, Matteo, Kozyrev, Sergey V., Sandling, Johanna K., Rönnblom, Lars, Eloranta, Maija-Leena, Syvänen, Ann-Christine, Leonard, Dag, Dahlqvist, Johanna, Lidén, Maria, Mathioudaki, Argyri, Meadows, Jennifer RS., Nordin, Jessika, Nordmark, Gunnel, Lundberg, Ingrid E., Notarnicola, Antonella, Padyukov, Leonid, Tjärnlund, Anna, Dastmalchi, Maryam, Eriksson, Daniel, Molberg, Øyvind, Andersson, Helena, Lindblad-Toh, Kerstin, Farias, Fabiana H.G., Wahren-Herlenius, Marie, Jalal, Awat, Hanna, Balsam, Hellström, Helena, Husmark, Tomas, Häggström, Åsa, Svärd, Anna, Skogh, Thomas, Diederichsen, Louise Pyndt, Lamb, Janine A., Rothwell, Simon, Chinoy, Hector, Cooper, Robert G., Pielberg, Gerli Rosengren, Lobell, Anna, Karlsson, Åsa, Murén, Eva, Ahlgren, Kerstin M., Andersson, Göran, Landegren, Nils, Kämpe, Olle, Söderkvis, Peter, Leclair, Valérie, Galindo-Feria, Angeles S., Kryštůfková, Olga, Zargar, Sepehr Sarrafzadeh, Mann, Herman, Klein, Martin, Tansley, Sarah, McHugh, Neil, Vencovský, Jiri, Holmqvist, Marie, and Diaz-Gallo, Lina-Marcela
- Published
- 2023
- Full Text
- View/download PDF
9. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
- Author
-
Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Castro Coello, Vanessa V, Haye Salinas, María J, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria S, Medina, María A, Savio, Veronica, Rojas Tessel, Romina, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Maria A, Rodriguez Gil, Gustavo F, Risueño, Fabian, Quaglia, Maria I, Scafati, Julia, Cuchiaro, Natalia L, Rebak, Jonathan E, Pineda, Susana I, Calvo, María E, Picco, Eugenia, Yanzi, Josefina G, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta S, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José L, Kisluk, Boris, Castaños Menescardi, Maria S, Gallo, Rosana, Martire, María V, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina S, Aeschlimann, Carolina, Subils, Gisela, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra L, Pinheiro, Marcelo, Ibáñez, Sebastián, Chassin Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešić, Marko, Anić, Branimir, Ćulo, Melanie-Ivana, Pavelić, Tea A, Stranski, Kristina K, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela M, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zazueta Montiel, Beatriz E, Castillo Ortiz, Angel A, Zamora Tehozol, Erick, Vega Morales, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez Reyna, Tatiana S, Rull Gabayet, Marina, Alpízar Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte Gil, Manuel, Nowakowski, Jarosław, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria M, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Mičeková, Dagmar, Capova, Lubica, Macejova, Zelmira, Šteňová, Emőke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre Rubio, Natalia, Alegre Sancho, Juan J, Corteguera Coro, Montserrat, Cobeta Garcia, Juan C, Torres Martin, Maria C, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd K, Akar, Servet, Icacan, Ozan C, ÇELİK, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline M, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, Todd, Derrick, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen, Webb Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Ezzati, Fatemeh, Parks, Deborah, Karp, David, Quiceno, Guillermo, Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Lopes Marques, Claudia D, Pileggi, Gecilmara C S, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, and Yazdany, Jinoos
- Published
- 2022
- Full Text
- View/download PDF
10. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
- Author
-
Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C
- Published
- 2021
- Full Text
- View/download PDF
11. Collaborative research in myositis-related disorders: MIHRA, a global shared community model
- Author
-
Saketkoo, Lesley Ann, primary, Paik, Julie J., additional, Alexanderson, Helene, additional, Dimachkie, Mazen M., additional, Ernste, Floranne C., additional, Naddaf, Elie, additional, Shafranski, Barbara, additional, Gupta, Latika, additional, Mecoli, Christopher A., additional, Saygin, Didem, additional, Albayda, Jemima, additional, Basharat, Pari, additional, Day, Jessica A., additional, Valenzuela, Antonia, additional, Bromley, Rachel, additional, de Groot, Ingrid, additional, Edison, Suzanne E., additional, Lanis, Aviya, additional, Lood, Christian, additional, Regardt, Malin, additional, Yi, Belina Y., additional, Benitez, Alejandro C., additional, Chinoy, Hector, additional, Christopher-Stine, Lisa, additional, Isenberg, David A., additional, Lang, Bianca, additional, Oddis, Chester V., additional, van Royen, Annet, additional, Vencovsky, Jiri, additional, Werth, Victoria P., additional, and Machado, Pedro M., additional
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical Features of Myositis: Muscular Manifestations
- Author
-
Vencovsky, Jiri, Aggarwal, Rohit, editor, and Oddis, Chester V., editor
- Published
- 2020
- Full Text
- View/download PDF
13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., Østergaard, Mikkel, Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., and Østergaard, Mikkel
- Abstract
Objective To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, di, Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex
- Published
- 2024
14. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., primary, Rugbjerg, Kathrine, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon H., additional, Jacobsson, Lennart, additional, Loft, Anne G., additional, Iannone, Florenzo, additional, Fagerli, Karen M., additional, Vencovsky, Jiri, additional, Santos, Maria J., additional, Möller, Burkhard, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Cefle, Ayse, additional, Eklund, Kari, additional, Codreanu, Catalin, additional, Jones, Gareth, additional, van der Sande, Marleen, additional, Wallman, Johan K., additional, Sebastiani, Marco, additional, Michelsen, Brigitte, additional, Závada, Jakub, additional, Nissen, Michael J., additional, Sanchez-Piedra, Carlos, additional, Tomšič, Matija, additional, Love, Thorvardur J., additional, Relas, Heikki, additional, Mogosan, Corina, additional, Hetland, Merete L., additional, and Østergaard, Mikkel, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Deciphering miRNA Signatures in Axial Spondyloarthritis: The Link between miRNA-1-3p and Pro-Inflammatory Cytokines
- Author
-
Prokopcova, Aneta, primary, Baloun, Jiri, additional, Bubova, Kristyna, additional, Gregova, Monika, additional, Forejtova, Sarka, additional, Horinkova, Jana, additional, Husakova, Marketa, additional, Mintalova, Katerina, additional, Cervenak, Vladimir, additional, Tomcik, Michal, additional, Vencovsky, Jiri, additional, Pavelka, Karel, additional, and Senolt, Ladislav, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
- Author
-
Smolen, Josef S, van Vollenhoven, Ronald, Kavanaugh, Arthur, Strand, Vibeke, Vencovsky, Jiri, Schiff, Michael, Landewé, Robert, Haraoui, Boulos, Arendt, Catherine, Mountian, Irina, Carter, David, and van der Heijde, Désirée
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Patient Safety ,Arthritis ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Adult ,Aged ,Antirheumatic Agents ,Arthritis ,Rheumatoid ,Certolizumab Pegol ,Dose-Response Relationship ,Drug ,Drug Administration Schedule ,Drug Therapy ,Combination ,Female ,Humans ,Infections ,Kaplan-Meier Estimate ,Male ,Methotrexate ,Middle Aged ,Time Factors ,Treatment Outcome ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
IntroductionAs patients with rheumatoid arthritis (RA) receive treatment with anti-tumour necrosis factors over several years, it is important to evaluate their long-term safety and efficacy. The objective of this study was to examine the safety and benefits of certolizumab pegol (CZP)+methotrexate (MTX) treatment for almost 5 years in patients with RA.MethodsPatients who completed the 24-week Rheumatoid Arthritis Prevention of Structural Damage (RAPID) 2 randomized controlled trial (RCT; NCT00160602), or who were American College of Rheumatology (ACR) 20 non-responders at Week 16, entered the open-label extension (OLE; NCT00160641). After ≥6 months treatment with CZP 400 mg every two weeks (Q2W), dose was reduced to 200 mg Q2W, the approved maintenance dose. Safety data are presented from all patients who received ≥1 dose CZP (Safety population, n=612). Efficacy data are presented to Week 232 for the intent-to-treat (ITT, n=492) and Week 24 CZP RCT Completer (n=342) populations, and through 192 weeks of dose-reduction for the Dose-reduction population (patients whose CZP dose was reduced to 200 mg, n=369). Radiographic progression (modified total Sharp score change from RCT baseline >0.5) to Week 128 is reported for the Week 24 CZP Completers.ResultsIn the RCT, 619 patients were randomized to CZP+MTX (n=492) or placebo+MTX (n=127). Overall, 567 patients (91.6%) entered the OLE: 447 CZP and 120 placebo patients. Of all randomized patients, 358 (57.8%) were ongoing at Week 232. Annual drop-out rates during the first four years ranged from 8.4-15.0%. Event rates per 100 patient-years were 163.0 for adverse events (AEs) and 15.7 for serious AEs. Nineteen patients (3.1%) had fatal AEs (incidence rate=0.8). Clinical improvements in the RCT were maintained to Week 232 in the CZP Completers: mean Disease Activity Score 28 (Erythrocyte Sedimentation Rate) change from baseline was -3.4 and ACR20/50/70 responses 68.4%/47.1%/25.1% (non-responder imputation). Similar improvements observed in the ITT were maintained following dose-reduction. 73.2% of CZP Completers had no radiographic progression at Week 128.ConclusionsIn patients with active RA despite MTX therapy, CZP was well tolerated, with no new safety signals identified. CZP provided sustained improvements in clinical outcomes for almost 5 years.Trial registrationClinicalTrials.gov, NCT00160602 and NCT00160641 . Registered 8 September 2005.
- Published
- 2015
17. Idiopathic inflammatory myopathies
- Author
-
Lundberg, Ingrid E., Fujimoto, Manabu, Vencovsky, Jiri, Aggarwal, Rohit, Holmqvist, Marie, Christopher-Stine, Lisa, Mammen, Andrew L., and Miller, Frederick W.
- Published
- 2021
- Full Text
- View/download PDF
18. Polymyositis: does it really exist as a distinct clinical subset?
- Author
-
Leclair, Valérie, Notarnicola, Antonella, Vencovsky, Jiri, and Lundberg, Ingrid E.
- Published
- 2021
- Full Text
- View/download PDF
19. Cardiovascular risk in myositis patients compared with the general population.
- Author
-
Oreska, Sabina, Storkanova, Hana, Pekacova, Aneta, Kudlicka, Jaroslav, Tuka, Vladimir, Mikes, Ondrej, Krupickova, Zdislava, Satny, Martin, Chytilova, Eva, Kvasnicka, Jan, Spiritovic, Maja, Hermankova, Barbora, Cesak, Petr, Rybar, Marian, Pavelka, Karel, Senolt, Ladislav, Mann, Herman, Vencovsky, Jiri, Vrablik, Michal, and Tomcik, Michal
- Subjects
CARDIOVASCULAR diseases risk factors ,MUSCLE diseases ,BODY composition ,BLOOD pressure ,ANKLE brachial index ,CAROTID artery diseases ,AGE distribution ,RISK assessment ,PULSE wave analysis ,SYMPTOMS ,RESEARCH funding ,MYOSITIS ,LONGITUDINAL method ,LIPIDS ,DISEASE risk factors ,DISEASE complications - Abstract
Objectives We aimed to evaluate cardiovascular (CV) risk in patients with idiopathic inflammatory myopathies (IIM) compared with healthy controls (HC) and to assess its association with disease-specific features. Methods Ninety IIM patients and 180 age-/sex-matched HC were included. Subjects with a history of CV disease (angina pectoris, myocardial infarction and cerebrovascular/peripheral arterial vascular events) were excluded. All participants were prospectively recruited and underwent examinations of carotid intima–media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition. The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE) and its modifications. Results Compared with HC, IIM patients had a significantly higher prevalence of traditional CV risk factors, carotid artery disease (CARD), abnormal ABI and PWV. After propensity score matching (using traditional CV risk factors), the prevalence of CARD and pathological PWV remained significantly higher in IIM than HC. No significant difference in SCORE was observed. The most unfavourable CV risk profile was observed in patients with necrotizing myopathy, especially in statin-induced anti-HMGCR
+ patients. The calculated CV risk scores by SCORE, SCORE2 and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to CIMT and the presence of carotid plaques. SCORE was demonstrated to be most inaccurate in predicting CV risk in IIM. Age, disease activity, lipid profile, body composition parameters and blood pressure were the most significant predictors of CV risk in IIM patients. Conclusion Significantly higher prevalence of traditional risk factors and subclinical atherosclerosis was observed in IIM patients compared with HC. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
20. Clinical Features of Myositis: Muscular Manifestations
- Author
-
Vencovsky, Jiri, primary
- Published
- 2019
- Full Text
- View/download PDF
21. Cardiovascular risk in myositis patients compared with the general population
- Author
-
Oreska, Sabina, primary, Storkanova, Hana, additional, Pekacova, Aneta, additional, Kudlicka, Jaroslav, additional, Tuka, Vladimir, additional, Mikes, Ondrej, additional, Krupickova, Zdislava, additional, Satny, Martin, additional, Chytilova, Eva, additional, Kvasnicka, Jan, additional, Spiritovic, Maja, additional, Hermankova, Barbora, additional, Cesak, Petr, additional, Rybar, Marian, additional, Pavelka, Karel, additional, Senolt, Ladislav, additional, Mann, Herman, additional, Vencovsky, Jiri, additional, Vrablik, Michal, additional, and Tomcik, Michal, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Novel SomaticUBA1Variant in a Patient With VEXAS Syndrome
- Author
-
Stiburkova, Blanka, primary, Pavelcova, Katerina, additional, Belickova, Monika, additional, Magaziner, Samuel J., additional, Collins, Jason C., additional, Werner, Achim, additional, Beck, David B., additional, Balajkova, Veronika, additional, Salek, Cyril, additional, Vostry, Martin, additional, Mann, Herman, additional, and Vencovsky, Jiri, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.
- Author
-
Kim, Hanna, Saygin, Didem, Douglas, Christian, Wilkerson, Jesse, Erman, Brian, Pistorio, Angela, McGrath, John A, Reed, Ann M, Oddis, Chester V, Bracaglia, Claudia, Royen-Kerkhof, Annet van, Bica, Blanca, Dolezalova, Pavla, Ferriani, Virginia P L, Flato, Berit, Bernard-Medina, Ana G, Herlin, Troels, Miller, Frederick W, Vencovsky, Jiri, and Ruperto, Nicolino
- Subjects
DRUG efficacy ,RITUXIMAB ,CONSENSUS (Social sciences) ,STATISTICS ,DERMATOMYOSITIS ,HEALTH outcome assessment ,TREATMENT effectiveness ,MUSCLE strength ,RESEARCH funding ,DATA analysis ,SENSITIVITY & specificity (Statistics) ,EVALUATION ,CHILDREN - Abstract
Objectives The 2016 ACR-EULAR Response Criteria for JDM was developed as a composite measure with differential weights of six core set measures (CSMs) to calculate a Total Improvement Score (TIS). We assessed the contribution of each CSM, representation of muscle-related and patient-reported CSMs towards improvement, and frequency of CSM worsening across myositis response criteria (MRC) categories in validation of MRC. Methods Data from JDM patients in the Rituximab in Myositis trial (n = 48), PRINTO JDM trial (n = 139), and consensus patient profiles (n = 273) were included. Observed vs expected CSM contributions were compared using Sign test. Characteristics of MRC categories were compared by Wilcoxon tests with Bonferroni adjustment. Spearman correlation of changes in TIS and individual CSMs were examined. Agreement between physician-assessed change and MRC categories was evaluated by weighted Cohen's kappa. Results Of 457 JDM patients with IMACS CSMs and 380 with PRINTO CSMs, 9–13% had minimal, 19–23% had moderate and 41–50% had major improvement. The number of improved and absolute percentage change of CSMs increased by MRC improvement level. Patients with minimal improvement by MRC had a median of 0–1 CSM worsened, and those with moderate/major improvement had a median of zero worsening CSMs. Of patients improved by MRC, 94–95% had improvement in muscle strength and 93–95% had improvement in ≥ 1 patient-reported CSM. IMACS and PRINTO CSMs performed similarly. Physician-rated change and MRC improvement categories had moderate-to-substantial agreement (Kappa 0.5–0.7). Conclusion The ACR-EULAR MRC perform consistently across multiple studies, supporting its further use as an efficacy end point in JDM trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.
- Author
-
Saygin, Didem, Kim, Hanna, Douglas, Christian, Erman, Brian, Wilkerson, Jesse, McGrath, John A, Oddis, Chester V, Lundberg, Ingrid E, Amato, Anthony A, Torre, Ignacio García-De La, Chinoy, Hector, Fiorentino, David, Chung, Lorinda, Song, Yeong-Wook, Miller, Frederick W, Ruperto, Nicolino, Vencovsky, Jiri, Aggarwal, Rohit, Rider, Lisa G, and (IMACS), for the International Myositis Assessment and Clinical Studies Group
- Subjects
DRUG efficacy ,RITUXIMAB ,DERMATOMYOSITIS ,POLYMYOSITIS ,CLINICAL trials ,RHEUMATOLOGY ,REGRESSION analysis ,HEALTH outcome assessment ,RHEUMATOLOGISTS ,COMPARATIVE studies ,DESCRIPTIVE statistics ,RESEARCH funding ,PHYSICIANS ,ETANERCEPT ,ABATACEPT ,MEDICAL needs assessment ,EVALUATION ,ADULTS - Abstract
Objective The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening. Methods Data from adult dermatomyositis/polymyositis patients in the rituximab (n = 147), etanercept (n = 14), and abatacept (n = 19) trials, and consensus patient profiles (n = 232) were evaluated. The Total Improvement Score (TIS), number of improving vs worsening CSMs, frequency of improvement with and without muscle-related CSMs, and contribution of PROM were evaluated by MRC category. Regression analysis was performed to assess contribution of each CSM to the MRC. Results Of 412 adults with dermatomyositis/polymyositis, there were 37%, 24%, 25%, and 14% with no, minimal, moderate, and major MRC improvement, respectively. The number of improving CSMs and absolute percentage change in all CSMs increased by improvement category. In minimal-moderate improvement, only physician-reported disease activity contributed significantly more than expected by MRC. Of patients with at least minimal improvement, 95% had improvement in muscle-related measures and a majority (84%) had improvement in PROM. Patients with minimal improvement had worsening in a median of 1 CSM, and most patients with moderate-major improvement had no worsening CSMs. Physician assessment of change generally agreed with MRC improvement categories. Conclusion The ACR-EULAR MRC performs consistently across multiple studies, further supporting its use as an efficacy end point in future myositis therapeutic trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies
- Author
-
Rothwell, Simon, Amos, Christopher I, Miller, Frederick W, Rider, Lisa G, Lundberg, Ingrid E, Gregersen, Peter K, Vencovsky, Jiri, McHugh, Neil, Limaye, Vidya, Selva-O'Callaghan, Albert, Hanna, Michael G, Machado, Pedro M, Pachman, Lauren M, Reed, Ann M, Molberg, Øyvind, Benveniste, Olivier, Mathiesen, Pernille, Radstake, Timothy, Doria, Andrea, De Bleecker, Jan L, De Paepe, Boel, Maurer, Britta, Ollier, William E, Padyukov, Leonid, O'Hanlon, Terrance P, Lee, Annette, Wedderburn, Lucy R, Chinoy, Hector, and Lamb, Janine A
- Subjects
610 Medicine & health - Abstract
OBJECTIVES The idiopathic inflammatory myopathies (IIM) are heterogeneous diseases, thought to be initiated by immune activation in genetically predisposed individuals. In this study we imputed variants from the Immunochip array using a large reference panel to fine-map associations and identify novel associations in IIM. METHODS We analysed 2,565 Caucasian IIM samples collected through the Myositis Genetics Consortium (MYOGEN) and 10,260 ethnically-matched controls. We imputed 1,648,116 variants from the Immunochip array using the Haplotype Reference Consortium panel and conducted association analysis on IIM, and clinical and serological subgroups. RESULTS The human leukocyte antigen (HLA) locus was consistently the most significantly associated region. Four non-HLA regions reached genome-wide significance, three in the whole IIM cohort (SDK2 and LINC00924 - both novel, and STAT4), with evidence of independent variants in STAT4, and NAB1 in the polymyositis (PM) subgroup. We also found suggestive evidence of association with loci previously associated with other autoimmune rheumatic diseases (TEC and LTBR). We identified more significant associations than those previously reported in IIM, for STAT4 and DGKQ in the total cohort, for NAB1 and FAM167A-BLK loci in PM, and CCR5 in inclusion body myositis. We found enrichment of variants among DNase I hypersensitivity sites and histone marks associated with active transcription within blood cells. CONCLUSIONS We report novel and strong associations in IIM and PM, and localise signals to single genes and immune cell types. This article is protected by copyright. All rights reserved.
- Published
- 2023
26. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein
- Author
-
Hurnakova, Jana, Hulejova, Hana, Zavada, Jakub, Komarc, Martin, Cerezo, Lucie Andres, Mann, Herman, Vencovsky, Jiri, Pavelka, Karel, and Senolt, Ladislav
- Published
- 2018
- Full Text
- View/download PDF
27. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
- Author
-
Leclair, Valerie, Galindo-Feria, Angeles S., Rothwell, Simon, Krystufkova, Olga, Zargar, Sepehr Sarrafzadeh, Mann, Herman, Diederichsen, Louise Pyndt, Andersson, Helena, Klein, Martin, Tansley, Sarah, Rönnblom, Lars, Lindblad-Toh, Kerstin, Syvänen, Ann-Christine, Wahren-Herlenius, Marie, Sandling, Johanna K., McHugh, Neil, Lamb, Janine A., Vencovsky, Jiri, Chinoy, Hector, Holmqvist, Marie, Bianchi, Matteo, Padyukov, Leonid, Lundberg, Ingrid E., Diaz-Galloc, Lina-Marcela, Leclair, Valerie, Galindo-Feria, Angeles S., Rothwell, Simon, Krystufkova, Olga, Zargar, Sepehr Sarrafzadeh, Mann, Herman, Diederichsen, Louise Pyndt, Andersson, Helena, Klein, Martin, Tansley, Sarah, Rönnblom, Lars, Lindblad-Toh, Kerstin, Syvänen, Ann-Christine, Wahren-Herlenius, Marie, Sandling, Johanna K., McHugh, Neil, Lamb, Janine A., Vencovsky, Jiri, Chinoy, Hector, Holmqvist, Marie, Bianchi, Matteo, Padyukov, Leonid, Lundberg, Ingrid E., and Diaz-Galloc, Lina-Marcela
- Abstract
Background In patients with idiopathic inflammatory myopathies (IIM), autoantibodies are associated with specific clinical phenotypes suggesting a pathogenic role of adaptive immunity. We explored if autoantibody profiles are associated with specific HLA genetic variants and clinical manifestations in IIM. Methods We included 1348 IIM patients and determined the occurrence of 14 myositis-specific or-associated autoantibodies. We used unsupervised cluster analysis to identify autoantibody-defined subgroups and logistic regression to estimate associations with clinical manifestations, HLA-DRB1, HLA-DQA1, HLA-DQB1 alleles, and amino acids imputed from genetic information of HLA class II and I molecules. Findings We identified eight subgroups with the following dominant autoantibodies: anti-Ro52, -U1RNP, -PM/Scl,-Mi2,-Jo1,-Jo1/Ro52,-TIF1 gamma or negative for all analysed autoantibodies. Associations with HLA-DRB1*11, HLA-DRB1*15, HLA-DQA1*03, and HLA-DQB1*03 were present in the anti-U1RNP-dominated subgroup. HLA-DRB1*03, HLA-DQA1*05, and HLA-DQB1*02 alleles were overrepresented in the anti-PM/Scl and anti-Jo1/ Ro52-dominated subgroups. HLA-DRB1*16, HLA-DRB1*07 alleles were most frequent in anti-Mi2 and HLA- DRB1*01 and HLA-DRB1*07 alleles in the anti-TIF1 gamma subgroup. The HLA-DRB1*13, HLA-DQA1*01 and HLA-DQB1*06 alleles were overrepresented in the negative subgroup. Significant signals from variations in class I molecules were detected in the subgroups dominated by anti-Mi2, anti-Jo1/Ro52, anti-TIF1 gamma, and the negative subgroup. Interpretation Distinct HLA class II and I associations were observed for almost all autoantibody-defined subgroups. The associations support autoantibody profiles use for classifying IIM which would likely reflect underlying pathogenic mechanisms better than classifications based on clinical symptoms and/or histopathological features. Funding See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscr
- Published
- 2023
- Full Text
- View/download PDF
28. 130 Low Gene Copy Numbers (GCN) of complement C4 and C4A deficiency are highly significant genetic risk factors for idiopathic inflammatory myopathies and its major subgroups
- Author
-
Zhou, Danlei, King, Emily, Rothwell, Simon, Kryštůfková, Olga, Notarnicola, Antonella, Coss, Samantha, Aziz, Rabheh, Miller, Katherine, Dang, Amanda, Yu, Richard, Drew, Joanne, Lundstrom, Emeli, Pachman, Lauren, Mamyrova, Gulnara, Curiel, Rodolfo, De Paepe, Boel, De Bleecker, Jan, Payton, Antony, Ollier, William, O'Hanlon, Terrance, Targoff, Ira, Flegel, Willy, Sivaraman, Vidya, Obele, Edward, Akoghlanian, Shoghik, Driest, Kyla, Spencer, Charles, Ling Wu, Yee, Nagaraja, Haikady, Ardoin, Stacy, Chinoy, Hector, Rider, Lisa, Miller, Frederick, Lundberg, Ingrid, Padyukov, Leonid, Vencovský, Jiří, Lamb, Janine, and Yu, Chack-Yung
- Published
- 2023
- Full Text
- View/download PDF
29. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
- Author
-
Taylor, Peter C., Saurigny, Didier, Vencovsky, Jiri, Takeuchi, Tsutomu, Nakamura, Tadashi, Matsievskaia, Galina, Hunt, Barbara, Wagner, Thomas, Souberbielle, Bernard, and for the NEXUS Study Group
- Published
- 2019
- Full Text
- View/download PDF
30. Distinct HLA Associations with Autoantibody-Defined Subgroups in Idiopathic Inflammatory Myopathies
- Author
-
Leclair, Valérie, primary, Galindo-Feria, Angeles S., additional, Rothwell, Simon, additional, Krystufkova, Olga, additional, Zargar, Sepehr Sarrafzadeh, additional, Mann, Herman, additional, Diederichsen, Louise Pyndt, additional, Andersson, Helena, additional, Klein, Martin, additional, Tansley, Sarah, additional, Rönnblom, Lars, additional, Lindblad-Toh, Kerstin, additional, Syvänen, Ann-Christine, additional, Wahren-Herlenius, Marie, additional, Sandling, Johanna K., additional, McHugh, Neil, additional, Lamb, Janine, additional, Vencovsky, Jiri, additional, Chinoy, Hector, additional, Holmqvist, Marie, additional, Bianchi, Matteo, additional, Padyukov, Leonid, additional, Lundberg, Ingrid E., additional, and Diaz-Gallo, Lina-Marcela, additional
- Published
- 2023
- Full Text
- View/download PDF
31. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
- Author
-
Kitas, George D., Abreu, Gabriel, Jedrychowicz-Rosiak, Krystyna, Miller, Jeffrey L., Nakov, Roumen, Panfilov, Seva, Vencovsky, Jiri, Wang, Millie, Weinblatt, Michael E., and White, William B.
- Published
- 2014
- Full Text
- View/download PDF
32. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study
- Author
-
Cordel, Nadège, primary, Dechelotte, Benoît, additional, Jouen, Fabienne, additional, Lamb, Janine A, additional, Chinoy, Hector, additional, New, Paul, additional, Vencovsky, Jiri, additional, Mann, Herman, additional, Galindo-Feria, Angeles S, additional, Dani, Lara, additional, Selva-O’Callaghan, Albert, additional, Werth, Victoria P, additional, Ravishankar, Adarsh, additional, Landon-Cardinal, Océane, additional, Tressières, Benoit, additional, and Boyer, Olivier, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
- Author
-
Izadi, Zara, primary, Gianfrancesco, Milena A, additional, Schmajuk, Gabriela, additional, Jacobsohn, Lindsay, additional, Katz, Patricia, additional, Rush, Stephanie, additional, Ja, Clairissa, additional, Taylor, Tiffany, additional, Shidara, Kie, additional, Danila, Maria I, additional, Wysham, Katherine D, additional, Strangfeld, Anja, additional, Mateus, Elsa F, additional, Hyrich, Kimme L, additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson-Tovey, Saskia, additional, Kearsley-Fleet, Lianne, additional, Schaefer, Martin, additional, Al-Emadi, Samar, additional, Sparks, Jeffrey A, additional, Hsu, Tiffany Y-T, additional, Patel, Naomi J, additional, Wise, Leanna, additional, Gilbert, Emily, additional, Duarte-García, Alí, additional, Valenzuela-Almada, Maria O, additional, Ugarte-Gil, Manuel F, additional, Ljung, Lotta, additional, Scirè, Carlo A, additional, Carrara, Greta, additional, Hachulla, Eric, additional, Richez, Christophe, additional, Cacoub, Patrice, additional, Thomas, Thierry, additional, Santos, Maria J, additional, Bernardes, Miguel, additional, Hasseli, Rebecca, additional, Regierer, Anne, additional, Schulze-Koops, Hendrik, additional, Müller-Ladner, Ulf, additional, Pons-Estel, Guillermo, additional, Tanten, Romina, additional, Nieto, Romina E, additional, Pisoni, Cecilia N, additional, Tissera, Yohana S, additional, Xavier, Ricardo, additional, Lopes Marques, Claudia D, additional, Pileggi, Gecilmara C S, additional, Robinson, Philip C, additional, Machado, Pedro M, additional, Sirotich, Emily, additional, Liew, Jean W, additional, Hausmann, Jonathan S, additional, Sufka, Paul, additional, Grainger, Rebecca, additional, Bhana, Suleman, additional, Gore-Massy, Monique, additional, Wallace, Zachary S, additional, Yazdany, Jinoos, additional, Dahou, Brahim, additional, Gómez, Gimena, additional, Roberts, Karen, additional, Baez, Roberto M, additional, Castro Coello, Vanessa V, additional, Haye Salinas, María J, additional, Maldonado, Federico N, additional, Reyes, Alvaro A, additional, Alle, Gelsomina, additional, Maldonado Ficco, Hernán, additional, Nieto, Romina, additional, Gobbi, Carla, additional, Tissera, Yohana, additional, Pisoni, Cecilia, additional, Paula, Alba, additional, Albiero, Juan A, additional, Schmid, Maria M, additional, Cosatti, Micaela, additional, Gamba, Maria J, additional, Leandro, Carlevaris, additional, Cusa, María A, additional, German, Noelia, additional, Bellomio, Veronica, additional, Takashima, Lorena, additional, Pera, Mariana, additional, Cogo, Karina, additional, Gálvez Elkin, Maria S, additional, Medina, María A, additional, Savio, Veronica, additional, Rojas Tessel, Romina, additional, Alamino, Rodolfo P, additional, Werner, Marina L, additional, Ornella, Sofía, additional, Casalla, Luciana, additional, de la Vega, Maria, additional, Severina, María, additional, García, Mercedes, additional, Gonzalez Lucero, Luciana, additional, Romeo, Cecilia, additional, Moyano, Sebastián, additional, Barbich, Tatiana, additional, Bertoli, Ana, additional, Baños, Andrea, additional, Petruzzelli, Sandra, additional, Matellan, Carla, additional, Conti, Silvana, additional, Lazaro, Maria A, additional, Rodriguez Gil, Gustavo F, additional, Risueño, Fabian, additional, Quaglia, Maria I, additional, Scafati, Julia, additional, Cuchiaro, Natalia L, additional, Rebak, Jonathan E, additional, Pineda, Susana I, additional, Calvo, María E, additional, Picco, Eugenia, additional, Yanzi, Josefina G, additional, Maid, Pablo, additional, Guaglianone, Debora, additional, Morbiducci, Julieta S, additional, Porta, Sabrina, additional, Herscovich, Natalia, additional, Velasco Zamora, José L, additional, Kisluk, Boris, additional, Castaños Menescardi, Maria S, additional, Gallo, Rosana, additional, Martire, María V, additional, Maldini, Carla, additional, Goizueta, Cecilia, additional, de la Vega Fernandez, Sabrina S, additional, Aeschlimann, Carolina, additional, Subils, Gisela, additional, Rath, Eva, additional, Piette, Yves, additional, Devinck, Mieke, additional, Maeyaert, Bea, additional, Machado Ribeiro, Francinne, additional, Euzebio Ribeiro, Sandra L, additional, Pinheiro, Marcelo, additional, Ibáñez, Sebastián, additional, Chassin Trubert, Anne-Marie, additional, Dong, Lingli, additional, Cajas, Lui, additional, Barešić, Marko, additional, Anić, Branimir, additional, Ćulo, Melanie-Ivana, additional, Pavelić, Tea A, additional, Stranski, Kristina K, additional, Karanovic, Boris, additional, Vencovsky, Jiri, additional, Píchová, Marta, additional, Filkova, Maria, additional, Hamoud, Hesham, additional, Vassilopoulos, Dimitrios, additional, Guzman Melgar, Gabriela M, additional, So, Ho, additional, Király, Márta, additional, Vojdanian, Mahdi, additional, Balbir Gurman, Alexandra, additional, Abutiban, Fatemah, additional, Zepa, Julija, additional, Bulina, Inita, additional, Bukauskiene, Loreta, additional, Zazueta Montiel, Beatriz E, additional, Castillo Ortiz, Angel A, additional, Zamora Tehozol, Erick, additional, Vega Morales, David, additional, Cervántes Rosete, Diana, additional, Martín Nares, Eduardo, additional, Rodriguez Reyna, Tatiana S, additional, Rull Gabayet, Marina, additional, Alpízar Rodríguez, Deshiré, additional, Irazoque, Fedra, additional, Jimenez, Xochitl, additional, Geurts van Bon, Lenny, additional, Zijlstra, Theo, additional, Hoekstra, Monique, additional, Al Adhoubi, Nasra, additional, Salim, Babur, additional, Giraldo, Enrique, additional, Salinas, Ariel, additional, Ugarte Gil, Manuel, additional, Nowakowski, Jarosław, additional, Conway, Richard, additional, Flood, Rachael, additional, McCarthy, Geraldine, additional, Felea, Ioana, additional, Filipescu, Ileana, additional, Rednic, Simona, additional, Groseanu, Laura, additional, Tamas, Maria M, additional, Mlynarikova, Vanda, additional, Skamlova, Martina, additional, Zlnay, Martin, additional, Mičeková, Dagmar, additional, Capova, Lubica, additional, Macejova, Zelmira, additional, Šteňová, Emőke, additional, Raffayova, Helena, additional, Belakova, Gabriela, additional, Strakova, Eva, additional, Senčarová, Marieta, additional, Žlnayová, Soňa, additional, Sabová, Anna, additional, Spisakova, Daniela, additional, Oetterová, Mária, additional, Lukacova, Olga, additional, Bakosova, Martina, additional, Hocevar, Alojzija, additional, de la Torre Rubio, Natalia, additional, Alegre Sancho, Juan J, additional, Corteguera Coro, Montserrat, additional, Cobeta Garcia, Juan C, additional, Torres Martin, Maria C, additional, Campos, Jose, additional, Gomez Puerta, Jose A, additional, Yardimci, Gozd K, additional, Akar, Servet, additional, Icacan, Ozan C, additional, ÇELİK, Selda, additional, Vasylets, Viktoriia, additional, Yeoh, Su-Ann, additional, Vandevelde, Claire, additional, Dunt, Sasha, additional, Leeder, Jane, additional, Macphie, Elizabeth, additional, Salerno, Rosaria, additional, Graver, Christine, additional, Williams, Katie, additional, O'Reilly, Sheila, additional, Devine, Kirsty, additional, Tyler, Jennifer, additional, Warner, Elizabeth, additional, Pilcher, James, additional, Patel, Samir, additional, Nikiphorou, Elena, additional, Chadwick, Laura, additional, Jones, Caroline M, additional, Harrison, Beverley, additional, Thornton, Lucy, additional, O'Kane, Diana, additional, Fusi, Lucia, additional, Low, Audrey, additional, Horton, Sarah, additional, Jatwani, Shraddha, additional, Baig, Sara, additional, Bajwa, Hammad, additional, Berglund, Vernon, additional, Dahle, Angela, additional, Dorman, Walter, additional, Hargrove, Jody, additional, Hilton, Maren, additional, Lebedoff, Nicholas, additional, Leonard, Susan, additional, Morgan, Jennifer, additional, Pfeifer, Emily, additional, Skemp, Archibald, additional, Wilson, Jeffrey, additional, Wolff, Anne, additional, Cepeda, Eduardo, additional, Todd, Derrick, additional, Hare, Denise, additional, Calabrese, Cassandra, additional, Adams, Christopher, additional, Khosroshahi, Arezou, additional, Kilian, Adam, additional, White, Douglas, additional, Winter, Melanie, additional, Fields, Theodore, additional, Siegel, Caroline, additional, Daver, Nicole, additional, Harvey, Melissa, additional, Kramer, Neil, additional, Lamore, Concetta, additional, Hogarty, Suneya, additional, Yeter, Karen, additional, Siddique, Faizah, additional, Ban, Byung, additional, Tanner, Tamar, additional, Ruderman, Eric, additional, Davis, William, additional, Quinet, Robert, additional, Scopelitis, Evangeline, additional, Toribio, Karen, additional, Webb Detiege, Tameka, additional, Zakem, Jerald, additional, Abbass, Khurram, additional, Kepecs, Gilbert, additional, Miranda, Lilliam, additional, Guma, Michael, additional, Haikal, Ammar, additional, Mody, Sushama, additional, Mueller, Daric, additional, Jayatilleke, Arundathi, additional, Zell, JoAnn, additional, Bays, Alison, additional, Dao, Kathryn, additional, Ezzati, Fatemeh, additional, Parks, Deborah, additional, Karp, David, additional, and Quiceno, Guillermo, additional
- Published
- 2022
- Full Text
- View/download PDF
34. The EuroMyositis registry: an international collaborative tool to facilitate myositis research
- Author
-
Lilleker, James B, Vencovsky, Jiri, Wang, Guochun, Wedderburn, Lucy R, Diederichsen, Louise Pyndt, Schmidt, Jens, Oakley, Paula, Benveniste, Olivier, Danieli, Maria Giovanna, Danko, Katalin, Thuy, Nguyen Thi Phuong, Vazquez-Del Mercado, Monica, Andersson, Helena, De Paepe, Boel, deBleecker, Jan L, Maurer, Britta, McCann, Liza J, Pipitone, Nicolo, McHugh, Neil, Betteridge, Zoe E, New, Paul, Cooper, Robert G, Ollier, William E, Lamb, Janine A, Krogh, Niels Steen, Lundberg, Ingrid E, Chinoy, Hector, D’hose, Sophie, Tian, Xin Lu,xiaolan, Mann, Herman, Kryštufková, Olga, Pleštilová, Lenka, Barochová,katerina kubínová, Martin Klein,tereza, Gelardi, Chiara, Pedini, Veronica, Cardinaletti, Paolo, Jara, Luis J, Saavedra, Miguel A, Cruz-reyes, Claudia V, Vera-lastra, Olga, Andrade-ortega, Lilia, Medrano-ramírez, Gabriel, Satoh, Minoru, Salazar-páramo, Mario, Gomez-bañuelos, Eduardo, Aguilar-arreola, Jorge, Durán-barragán, Sergio, Navarro-hernandez, Rosa Elena, Petri, Marcelo H, Molberg, Øyvind, Dastmalchi, Maryam, Notarnicola, Antonella, Gheorghe, Karina, Rönnelid, Johan, Liden, Maria, Hanna, Balsam, Jalal, Awat, Hellström, Helena, Martineus, Jehns Christian, Ngoc lan, Nguyen Thi, Padyukov, Leonid, New, Paul, Platt, Hazel, Rothwell, Simon, Ahmed, Yasmeen, Armstrong, Raymond, Bernstein, Robert, Black, Carol, Bowman, Simon, Bruce, Ian, Butler, Robin, Carty, John, Chattopadhyay, Chandra, Chelliah, Easwaradhas, Clarke, Fiona, Dawes, Peter, Denton, Christopher, Devlin, Joseph, Edwards, Christopher, Emery, Paul, Fordham, John, Fraser, Alexander, Gaston, Hill, Gordon, Patrick, Griffiths, Bridget, Gunawardena, Harsha, Hall, Frances, Hanna, Michael, Harrison, Beverley, Hay, Elaine, Hilton-jones, David, Horden, Lesley, Isaacs, John, Isenberg, David, Jones, Adrian, Kamath, Sanjeet, Kennedy, Thomas, Kitas, George, Klimiuk, Peter, Knights, Sally, Lambert, John, Lanyon, Peter, Laxminarayan, Ramasharan, Lecky, Bryan, Luqmani, Raashid, Machado, Pedro, Marks, Jeffrey, Martin, Michael, Mcgonagle, Dennis, Mchugh, Neil, Mckenna, Francis, Mclaren, John, Mcmahon, Michael, Mcrorie, Euan, Merry, Peter, Miles, Sarah, Miller, James, Nicholls, Anne, Nixon, Jennifer, Ong, Voon, Over, Katherine, Packham, John, Pipitone, Nicolo, Plant, Michael, Pountain, Gillian, Pullar, Thomas, Roberts, Mark, Sanders, Paul, Scott, David, Scott, David, Shadforth, Michael, Sheeran, Thomas, Srinivasan, Arul, Swinson, David, Teh, Lee-suan, Webley, Michael, Williams, Brian, and Winer, Jonathan
- Published
- 2018
- Full Text
- View/download PDF
35. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
- Author
-
Tjärnlund, Anna, Tang, Quan, Wick, Cecilia, Dastmalchi, Maryam, Mann, Herman, Tomasová Studýnková, Jana, Chura, Radka, Gullick, Nicola J, Salerno, Rosaria, Rönnelid, Johan, Alexanderson, Helene, Lindroos, Eva, Aggarwal, Rohit, Gordon, Patrick, Vencovsky, Jiri, and Lundberg, Ingrid E
- Published
- 2018
- Full Text
- View/download PDF
36. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
- Author
-
Weinblatt, Michael E., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovsky, Jiri, Guo, Xiang, White, Wendy I., Ryan, Patricia C., Godwood, Alex, Albulescu, Marius, Close, David, and Burmester, Gerd R.
- Published
- 2018
- Full Text
- View/download PDF
37. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
- Author
-
Lundberg, Ingrid E, Tjärnlund, Anna, Bottai, Matteo, Werth, Victoria P, Pilkington, Clarissa, Visser, Marianne de, Alfredsson, Lars, Amato, Anthony A, Barohn, Richard J, Liang, Matthew H, Singh, Jasvinder A, Aggarwal, Rohit, Arnardottir, Snjolaug, Chinoy, Hector, Cooper, Robert G, Dankó, Katalin, Dimachkie, Mazen M, Feldman, Brian M, Torre, Ignacio Garcia-De La, Gordon, Patrick, Hayashi, Taichi, Katz, James D, Kohsaka, Hitoshi, Lachenbruch, Peter A, Lang, Bianca A, Li, Yuhui, Oddis, Chester V, Olesinska, Marzena, Reed, Ann M, Rutkowska-Sak, Lidia, Sanner, Helga, Selva-O’Callaghan, Albert, Song, Yeong-Wook, Vencovsky, Jiri, Ytterberg, Steven R, Miller, Frederick W, and Rider, Lisa G
- Published
- 2017
- Full Text
- View/download PDF
38. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects
- Author
-
Rider, Lisa G, Ruperto, Nicolino, Pistorio, Angela, Erman, Brian, Bayat, Nastaran, Lachenbruch, Peter A, Rockette, Howard, Feldman, Brian M, Huber, Adam M, Hansen, Paul, Oddis, Chester V, Lundberg, Ingrid E, Amato, Anthony A, Chinoy, Hector, Cooper, Robert G, Chung, Lorinda, Danko, Katalin, Fiorentino, David, García-De la Torre, Ignacio, Reed, Ann M, Wook Song, Yeong, Cimaz, Rolando, Cuttica, Rubén J, Pilkington, Clarissa A, Martini, Alberto, van der Net, Janjaap, Maillard, Susan, Miller, Frederick W, Vencovsky, Jiri, and Aggarwal, Rohit
- Published
- 2017
- Full Text
- View/download PDF
39. Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome.
- Author
-
Stiburkova, Blanka, Pavelcova, Katerina, Belickova, Monika, Magaziner, Samuel J., Collins, Jason C., Werner, Achim, Beck, David B., Balajkova, Veronika, Salek, Cyril, Vostry, Martin, Mann, Herman, and Vencovsky, Jiri
- Subjects
PROTEINS ,MYELODYSPLASTIC syndromes ,GENETIC mutation ,SEQUENCE analysis ,GENETIC variation ,GENETIC testing ,GENOME-wide association studies ,IMMUNOBLOTTING ,CASE studies ,AUTOINFLAMMATORY diseases ,SYMPTOMS - Abstract
Objective: Somatic mutations in UBA1 have recently been causally linked to a severe adult‐onset inflammatory condition referred to as VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Ubiquitin‐activating enzyme E1 (UBA‐1) is of fundamental importance to the modulation of ubiquitin homeostasis and to the majority of downstream ubiquitylation‐dependent cellular processes. Direct sequencing analysis of exon 3 containing the prevalent variants p.Met41Leu, p.Met41Val, and/or p.Met41Thr is usually used to confirm the disease‐associated mutations. Methods: We studied the clinical, biochemical, and molecular genetic characteristics of a 59‐year‐old man with a 2‐year history of arthritis, fever, night sweats, nonspecific skin rash, lymphadenopathy, and myelodysplastic syndrome with multilineage dysplasia. Results: The mutational analysis revealed a previously undescribed sequence variant c.1430G>C in exon 14 (p.Gly477Ala) in the gene UBA1. In vitro enzymatic analyses showed that p.Gly477Ala led to both decreased E1 ubiquitin thioester formation and E2 enzyme charging. Conclusion: We report a case of a patient of European ancestry with clinical manifestations of VEXAS syndrome associated with a newly identified dysfunctional UBA‐1 enzyme variant. Due to the patient's insufficient response to various immunosuppressive treatments, allogeneic hematopoietic stem cell transplantation was performed, which resulted in significant improvement of clinical and laboratory manifestations of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Identification of Novel Associations and Localization of Signals in Idiopathic Inflammatory Myopathies Using Genome‐Wide Imputation.
- Author
-
Rothwell, Simon, Amos, Christopher I., Miller, Frederick W., Rider, Lisa G., Lundberg, Ingrid E., Gregersen, Peter K., Vencovsky, Jiri, McHugh, Neil, Limaye, Vidya, Selva‐O'Callaghan, Albert, Hanna, Michael G., Machado, Pedro M., Pachman, Lauren M., Reed, Ann M., Molberg, Øyvind, Benveniste, Olivier, Mathiesen, Pernille, Radstake, Timothy, Doria, Andrea, and De Bleecker, Jan L.
- Subjects
GENETICS of autoimmune diseases ,POLYMYOSITIS ,SEROLOGY ,GENOMICS ,HAPLOTYPES ,HISTONES ,IMMUNITY ,RESEARCH funding ,MYOSITIS ,STATISTICAL models ,WHITE people ,RHEUMATISM - Abstract
Objective: The idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases thought to be initiated by immune activation in genetically predisposed individuals. We imputed variants from the ImmunoChip array using a large reference panel to fine‐map associations and identify novel associations in IIM. Methods: We analyzed 2,565 Caucasian IIM patient samples collected through the Myositis Genetics Consortium (MYOGEN) and 10,260 ethnically matched control samples. We imputed 1,648,116 variants from the ImmunoChip array using the Haplotype Reference Consortium panel and conducted association analysis on IIM and clinical and serologic subgroups. Results: The HLA locus was consistently the most significantly associated region. Four non‐HLA regions reached genome‐wide significance, SDK2 and LINC00924 (both novel) and STAT4 in the whole IIM cohort, with evidence of independent variants in STAT4, and NAB1 in the polymyositis (PM) subgroup. We also found suggestive evidence of association with loci previously associated with other autoimmune rheumatic diseases (TEC and LTBR). We identified more significant associations than those previously reported in IIM for STAT4 and DGKQ in the total cohort, for NAB1 and FAM167A‐BLK loci in PM, and for CCR5 in inclusion body myositis. We found enrichment of variants among DNase I hypersensitivity sites and histone marks associated with active transcription within blood cells. Conclusion: We found novel and strong associations in IIM and PM and localized signals to single genes and immune cell types. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies
- Author
-
Albrecht, Inka, Wick, Cecilia, Hallgren, Asa, Tjarnlund, Anna, Nagaraju, Kanneboyina, Andrade, Felipe, Thompson, Kathryn, Coley, William, Phadke, Aditi, Diaz-Gallo, Lina-Marcela, Bottai, Matteo, Nennesmo, Inger, Chemin, Karine, Herrath, Jessica, Johansson, Karin, Wikberg, Anders, Ytterberg, A. Jimmy, Zubarev, Roman A., Danielsson, Olof, Krystufkova, Olga, Vencovsky, Jiri, Landegren, Nils, Wahren-Herlenius, Marie, Padyukov, Leonid, Kampe, Olle, and Lundberg, Ingrid E.
- Subjects
Gene mutations -- Identification and classification -- Health aspects ,Medical research ,Medicine, Experimental ,Muscle diseases -- Genetic aspects -- Development and progression ,Autoimmunity -- Research ,Autoantibodies -- Genetic aspects ,Health care industry - Abstract
Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed [FHL1.sup.-]related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-[FHL1.sup.-]negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic [FHL1.sup.-]related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM., Introduction Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare systemic autoimmune diseases collectively called myositis, which causes progressive muscle weakness. Several forms ofthe disease, including polymyositis (PM), dermatomyositis [...]
- Published
- 2015
- Full Text
- View/download PDF
42. Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
- Author
-
Oreska, Sabina, primary, Storkanova, Hana, additional, Kudlicka, Jaroslav, additional, Tuka, Vladimir, additional, Mikes, Ondrej, additional, Krupickova, Zdislava, additional, Satny, Martin, additional, Chytilova, Eva, additional, Kvasnicka, Jan, additional, Spiritovic, Maja, additional, Hermankova, Barbora, additional, Cesak, Petr, additional, Rybar, Marian, additional, Pavelka, Karel, additional, Senolt, Ladislav, additional, Mann, Herman, additional, Vencovsky, Jiri, additional, Vrablik, Michal, additional, and Tomcik, Michal, additional
- Published
- 2022
- Full Text
- View/download PDF
43. The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels
- Author
-
Andrés Cerezo, Lucie, Kuklová, Markéta, Hulejová, Hana, Vernerová, Zdeňka, Pešáková, Vlasta, Pecha, Ondřej, Veigl, David, Haluzík, Martin, Pavelka, Karel, Vencovský, Jiří, and Šenolt, Ladislav
- Published
- 2013
- Full Text
- View/download PDF
44. 08.48 Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity
- Author
-
Oreska, Sabina, Spiritovic, Maja, Cesak, Petr, Marecek, Ondrej, Storkanova, Hana, Kubinova, Katerina, Klein, Martin, Vernerova, Lucie, Ruzickova, Olga, Becvar, Radim, Pavelka, Karel, Senolt, Ladislav, Mann, Herman, Vencovsky, Jiri, and Tomcik, Michal
- Published
- 2017
- Full Text
- View/download PDF
45. 08.49 Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients – preliminary data from a single-centre controlled study
- Author
-
Spiritovic, Maja, Smucrova, Hana, Oreska, Sabina, Storkanova, Hana, Cesak, Petr, Rathouska, Adela, Ruzickova, Olga, Mann, Herman, Pavelka, Karel, Senolt, Ladislav, Vencovsky, Jiri, Becvar, Radim, and Tomcik, Michal
- Published
- 2017
- Full Text
- View/download PDF
46. 08.47 Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity
- Author
-
Spiritovic, Maja, Oreska, Sabina, Cesak, Petr, Cesak, Michal, Storkanova, Hana, Kubinova, Katerina, Klein, Martin, Vernerova, Lucia, Ruzickova, Olga, Mann, Herman, Pavelka, Karel, Senolt, Ladislav, Vencovsky, Jiri, Becvar, Radim, and Tomcik, Michal
- Published
- 2017
- Full Text
- View/download PDF
47. 08.01 Heat shock protein 90 is increased in muscle tissue and plasma in idiopathic inflammatory myopathies
- Author
-
Storkanova, Hana, Krystufkova, Olga, Klein, Martin, Mann, Herman, Vernerova, Lucia, Spiritovic, Maja, Zamecnik, Josef, Pavelka, Karel, Senolt, Ladislav, Vencovsky, Jiri, and Tomcik, Michal
- Published
- 2017
- Full Text
- View/download PDF
48. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
- Author
-
Cordel, Nadège, Dechelotte, Benoît, Jouen, Fabienne, Lamb, Janine A, Chinoy, Hector, New, Paul, Vencovsky, Jiri, Mann, Herman, Galindo-Feria, Angeles S, Dani, Lara, Selva-O'Callaghan, Albert, Werth, Victoria P, Ravishankar, Adarsh, Landon-Cardinal, Océane, Tressières, Benoit, and Boyer, Olivier
- Subjects
TUMOR risk factors ,AUTOANTIBODIES ,DERMATOMYOSITIS ,RETROSPECTIVE studies ,GAMMA globulins ,RISK assessment ,IMMUNOASSAY ,CANCER patients ,ENZYME-linked immunosorbent assay ,DESCRIPTIVE statistics ,TRANSCRIPTION factors ,TUMOR markers ,CRYOPRESERVATION of organs, tissues, etc. ,CHEMICAL inhibitors ,ADULTS - Abstract
Objective To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM. Methods International multicentre retrospective study with the following inclusion criteria: (i) diagnosis of DM according to ENMC criteria; (ii) presence of anti-TIF1γ IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis and (iii) available baseline characteristics and follow-up data until the occurrence of cancer and/or a minimum follow-up of 1 year for patients without known cancer at diagnosis. Detection and quantification of anti-TIF1γ IgG2 aAb was done using the in-house ALBIA. In addition, a recent ELISA commercial kit was used for anti-TIF1γ IgG aAb quantification. Results A total of 132 patients (mean age 55±15 years) of whom 72 (54.5%) had an associated cancer were analysed. The association between the presence of cancer and the presence of anti-TIF1γ IgG2 aAb was statistically significant (P = 0.026), with an OR of 2.26 (95% CI: 1.10, 4.76). Patients with cancer displayed significantly higher anti-TIF1γ IgG2 aAb ALBIA values with a median value of 1.15 AU/ml (IQR: 0.14–9.76) compared with 0.50 AU/ml (IQR: 0.14–1.46) for patients without cancer (P = 0.042). In addition, patients with cancer displayed significantly higher anti-TIF1γ IgG aAb ELISA values with a median value of 127.5 AU/ml (IQR: 81.5–139.6) compared with 93.0 AU/ml (IQR: 54.0–132.9) for patients without cancer (P = 0.004). Conclusion These results suggest considering anti-TIF1γ IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 γ aAb-positive adult DM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Chemokines in Rheumatoid Arthritis
- Author
-
Plater-Zyberk, Christine, Vencovsky, Jiri, Power, Christine A., and Hébert, Caroline A., editor
- Published
- 1999
- Full Text
- View/download PDF
50. P222 Clinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry
- Author
-
Hum, Ryan M, primary, Lilleker, James B, additional, Lamb, Janine A, additional, Ollier, William E, additional, Wang, Guochung, additional, Wedderburn, Lucy R, additional, Diederichsen, Louise P, additional, Schmidt, Jens, additional, Oakley, Paula, additional, Benveniste, Olivier, additional, Danieli, Maria G, additional, Danko, Katalin, additional, Thuy, Nguyen T. P, additional, Mercado, Monica V. D, additional, Andersson, Helena, additional, Paepe, Boel D, additional, Bleecker, Jan L. D, additional, Maurer, Britta, additional, McCann, Liza J, additional, Pipitone, Nicolo, additional, McHugh, Neil, additional, New, Paul, additional, Vencovsky, Jiri, additional, Lundberg, Ingrid E, additional, and Chinoy, Hector, additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.